Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC

Adenomatous polyposis coli (APC) truncations occur in many colorectal cancers and are often associated with immune infiltration. The aim of this study was to determine whether a combination of Wnt inhibition with anti-inflammatory (sulindac) and/or proapototic (ABT263) drugs can reduce colon adenomas. Apcmin/+ and doublecortin-like kinase 1 (Dclk1)Cre/+;Apcfl/fl mice were exposed to dextran sulphate sodium (DSS) in their drinking water to promote the formation of colon adenomas. Mice were then treated with either a Wnt-signaling antagonist pyrvinium pamoate (PP), an anti-inflammatory agent sulindac or proapoptotic compound ABT263 or a combination of PP+ABT263, or PP+sulindac. Colon adenoma frequency, size, and T-cell abundance were measured. DSS treatment resulted in significant increases in colon adenoma number (P < 0.001, n > 5) and burden in Apcmin/+ (P < 0.01, n > 5) and Dclk1Cre/+;Apcfl/fl (P < 0.02, n > 5) mice. There was no effect on adenomas following treatment with PP in combination with ABT263. Adenoma number and burden were reduced with PP+sulindac treatment in Dclk1Cre/+;Apcfl/fl mice (P < 0.01, n > 17) and in Apcmin/+ mice (P < 0.001, n > 7) treated with sulindac or PP+sulindac with no detectable toxicity. PP treatment of Apcmin/+ mice increased the frequency of CD3+ cells in the adenomas. The combination of Wnt pathway inhibition with sulindac was more effective in Dclk1Cre/+;Apcfl/fl mice and provides an opportunity for killing Apc-mutant colon adenoma cells, indicating a strategy for both colorectal cancer prevention and potential new treatments for patients with advanced colorectal cancer. Outcomes from the results of this study may be translatable to the clinic for management of FAP and other patients with a high risk of developing colorectal cancer. Significance: Colorectal cancer is one of the most common cancers worldwide with limited therapeutic options. APC and other Wnt signaling mutations occur in the majority of colorectal cancers but there are currently no Wnt inhibitors in the clinic. The combination of Wnt pathway inhibition with sulindac provides an opportunity for killing Apc-mutant colon adenoma cells and suggests a strategy for colorectal cancer prevention and new treatments for patients with advanced colorectal cancer.

[1]  P. Wirapati,et al.  BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer , 2021, Cell Death & Differentiation.

[2]  A. Burgess,et al.  Dual Drug Targeting to Kill Colon Cancer Cells , 2021, bioRxiv.

[3]  J. Meyerhardt,et al.  Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes , 2020, JNCI cancer spectrum.

[4]  S. Fröhling,et al.  Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer , 2020, Cell Death & Disease.

[5]  P. Gibbs,et al.  Defining the susceptibility of colorectal cancers to BH3-mimetic compounds , 2020, Cell Death & Disease.

[6]  J. McNeil,et al.  Aspirin for Primary Prevention in Adults Older than 70 Years is Not Supported by High-Quality Trial Data and May Cause Harm. , 2020, The American journal of medicine.

[7]  Jason Park,et al.  The Association Between Wait Times for Colorectal Cancer Treatment and Health Care Costs: A Population-Based Analysis , 2019, Diseases of the colon and rectum.

[8]  W. Miltyk,et al.  Celecoxib in Cancer Therapy and Prevention - Review. , 2019, Current drug targets.

[9]  J. Luke,et al.  WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers , 2019, Clinical Cancer Research.

[10]  T. Gajewski,et al.  Impact of oncogenic pathways on evasion of antitumour immune responses , 2018, Nature Reviews Cancer.

[11]  Juan Zhao,et al.  Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein Kinase 1&agr;‐Dependent Inhibition of Wnt/&bgr;‐Catenin , 2017, The American journal of the medical sciences.

[12]  Yan Zhou,et al.  Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas , 2017, Gut.

[13]  T. Wang,et al.  Dclk1-expressing tuft cells: critical modulators of the intestinal niche? , 2017, American journal of physiology. Gastrointestinal and liver physiology.

[14]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[15]  Marnix Jansen,et al.  Bcl-2 is a critical mediator of intestinal transformation , 2016, Nature Communications.

[16]  Ethan Lee,et al.  Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis , 2014, PLoS ONE.

[17]  Andreas H. Nuber,et al.  Long-lived intestinal tuft cells serve as colon cancer-initiating cells. , 2014, The Journal of clinical investigation.

[18]  O. Sieber,et al.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. , 2013, Cancer cell.

[19]  Erinna F. Lee,et al.  Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. , 2012, Blood.

[20]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[21]  Bruce J. Aronow,et al.  The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor Suppressor , 2012, Cell.

[22]  Bruce J. Melancon,et al.  Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. , 2010, Nature chemical biology.

[23]  Hans Clevers,et al.  Lineage tracing in the intestinal epithelium. , 2010, Current protocols in stem cell biology.

[24]  Owen J. Sansom,et al.  Genetic Dissection of Differential Signaling Threshold Requirements for the Wnt/β-Catenin Pathway In Vivo , 2010, PLoS genetics.

[25]  J. Parkitna,et al.  Generation of Cre recombinase-expressing transgenic mice using bacterial artificial chromosomes. , 2009, Methods in molecular biology.

[26]  Hans Clevers,et al.  Crypt stem cells as the cells-of-origin of intestinal cancer , 2009, Nature.

[27]  Timothy H. Davis,et al.  Pyrvinium Targets the Unfolded Protein Response to Hypoglycemia and Its Anti-Tumor Activity Is Enhanced by Combination Therapy , 2008, PloS one.

[28]  C. Tse,et al.  Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models , 2008, Clinical Cancer Research.

[29]  H. Clevers,et al.  Identification of stem cells in small intestine and colon by marker gene Lgr5 , 2007, Nature.

[30]  K. Maclennan,et al.  Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. , 2004, Blood.

[31]  S T Pals,et al.  Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines , 2004, British Journal of Cancer.

[32]  C. Blum,et al.  Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac. , 2003, Carcinogenesis.

[33]  S. Piantadosi,et al.  Primary chemoprevention of familial adenomatous polyposis with sulindac , 2002 .

[34]  H. Cooper,et al.  The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. , 2001, Gastroenterology.

[35]  Nancy A. Jenkins,et al.  Recombineering: a powerful new tool for mouse functional genomics , 2001, Nature Reviews Genetics.

[36]  K. Kinzler,et al.  Landscaping the Cancer Terrain , 1998, Science.

[37]  T. Noda,et al.  Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. , 1997, Science.

[38]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[39]  K. Kinzler,et al.  Sulindac suppresses tumorigenesis in the Min mouse. , 1996, Carcinogenesis.

[40]  F. Giardiello,et al.  Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. , 1996, Gut.

[41]  P. Chambon,et al.  Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[43]  W. Bodmer,et al.  Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas , 1992, The Lancet.

[44]  K. Kinzler,et al.  Corrections and Clarifications: Multiple Intestinal Neoplasia Caused By a Mutation in the Murine Homolog of the APC Gene , 1992, Science.

[45]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[46]  H. Pitot,et al.  A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. , 1990, Science.

[47]  Takuji Tanaka,et al.  Dextran sodium sulfate strongly promotes colorectal carcinogenesis in ApcMin/+ mice: Inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms , 2006, International journal of cancer.

[48]  Philippe Soriano.  Generalized lacZ expression with the ROSA26 Cre reporter strain , 1999, Nature Genetics.